Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. News

Press releases

30.05.2018

DEINOVE and OLEOS expand their collaboration with the support of the Occitanie Region

A second cosmetic active ingredient will be developed as part of the collaboration between DEINOVE and Hallstar-Oléos. The Occitanie Region...
23.05.2018

General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...
22.05.2018

COLOR2B project: confirmed progress and outlook

The selected producer strain shows performance comparable to petrochemical products on the market today. The tests continue to validate the...
16.04.2018

DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration

HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...
13.04.2018

DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...
10.04.2018

DEINOVE introduces Phyt-n-Resist®, the first pure phytoene for skincare

Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...
29.03.2018

2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...
22.03.2018

DEINOVE expands its innovative antibiotic portfolio by signing a license option agreement with REDX PHARMA

The program developed by REDX PHARMA focuses on a new class of antibiotics aimed at treating the most lethal infections (caused by...
08.03.2018

DEINOVE collaborates with NAICONS to discover new antibiotics in the frame of the AGIR project

DEINOVE expands the AGIR project’s field of investigation for the discovery of novel antibiotic structures by accessing the strain bank of...
26.02.2018

DEINOVE announces the success of its cosmetic active ingredient’s production process industrialization

World premiere in Deinococcus fermentation successfully performed at the several cubic meters scale; The first batch of carotenoid...
  • « first
  • ‹ previous
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • next ›
  • last »

News

  • Press releases
  • Events
  • Media
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home